Taiho deal fills Japan gap in Faes' panoply of bilastine alliances
This article was originally published in Scrip
Executive Summary
The Otsuka group subsidiary Taiho Pharmaceutical has acquired development and commercialisation rights in Japan to Faes Farma's anti-allergic bilastine, expanding the product's reach into what the Spanish firm describes as the largest antihistamine market worldwide.